LY4086940 Timeline: The Public Record, in Order

Evidence timeline

LY4086940 is an Eli Lilly obesity candidate with very little disclosed. This page lists every public record we have found that names it, in date order, and says what each one does and does not tell us.

Reading the tags. Registry recordClinicalTrials.gov, the US government trial database. Lilly documentA slide deck Lilly published for investors. Patent, context onlyA Lilly patent that never names the code. Not mentionedA Lilly document checked that does not carry it. ScheduledA dated event still ahead. Third-party reportA tracker’s reading of a regulator’s public list, not confirmed by the regulator or Lilly.

The timeline

Oldest first. Each entry says what the document shows, what it leaves out, and links to the document itself.

1. Aug 8 to 152024
   Patent, context only

   A Lilly patent application on GIP, GLP-1 and glucagon tri-receptor agonists is published

   What it says. Lilly filed the application on January 31, 2024. The world version, WO2024163535A1, published August 8, 2024, and the US version, US 2024/0270821 A1, published August 15, 2024. The title is “GIP/GLP1/GCG tri-receptor agonists and uses thereof,” and the text says the polypeptides can be given under the skin or by mouth.

   What it leaves out. It never mentions LY4086940 or any other Lilly code, so it does not show that this patent covers the program. Treat it as background on what Lilly has described in this class, not as a link.

   Source: WO2024163535A1, US20240270821A1

2. Apr 252025
   Registry record

   ClinicalTrials.gov lists a phase 1 study of LY4086940

   What it says. The study, NCT06945419, is titled “A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes.” It was submitted April 18, first posted April 25 and started April 23, 2025. The sponsor is Eli Lilly and Company. The record describes four parts with oral dosing and a fifth with a single intravenous dose, at sites in Florida, Texas and Singapore.

   What it leaves out. No dose amounts, no mechanism, no drug class and no name other than the code.

   Source: NCT06945419

3. Jun 222025
   Lilly document

   Lilly’s ADA investor slides show an “oral GGG peptide”

   What it says. Slide 8 shows an oral GGG peptide labelled as a GLP-1, GIP and glucagon agonist, next to retatrutide, which carries the same receptor label. Slide 27 lists it again among oral and long-acting multifunctional incretins.

   What it leaves out. The slides do not name LY4086940 or GGG Tri-Agonist III beside this peptide. The shared “GGG” wording points that way, but Lilly does not say in these slides that they are the same molecule, and they give no sequence, dose or result.

   Source: Lilly ADA 2025 investor slides

4. Aug 72025
   Lilly document

   “GGG Tri-Agonist III” first appears on Lilly’s pipeline chart

   What it says. The Q2 2025 earnings deck lists a program called GGG Tri-Agonist III on slide 16, the pipeline chart. The Q4 2024 and Q1 2025 decks have no mention of the label.

   What it leaves out. No trial number, drug code or description comes with the label on that slide.

   Source: Lilly Q2 2025 earnings deck

5. Oct 302025
   Lilly document

   Lilly puts the label and the LY4086940 study in the same row

   What it says. In the Q3 2025 earnings deck, slide 16 (the pipeline chart, dated October 28, 2025) lists GGG Tri-Agonist III again. Slide 45, a list of select early-phase trials, has a row for it with NCT06945419, the LY4086940 study title, phase 1, 165 patients and both completion dates listed as April 2026.

   What it leaves out. This is the earliest Lilly document found that ties the label to the code. It gives no mechanism, structure or dose.

   Source: Lilly Q3 2025 earnings deck

6. Feb 42026
   Lilly document

   The Q4 2025 deck shows a larger study and a later finish line

   What it says. Slide 18 (pipeline chart, dated February 3, 2026) still lists GGG Tri-Agonist III. Slide 51 repeats the NCT06945419 row with 201 patients and the same April 2026 completion dates, using ClinicalTrials.gov data from January 23, 2026.

   What it leaves out. Still no mechanism, structure or dose. It is the last Lilly deck checked that carries the label.

   Source: Lilly Q4 2025 earnings deck

7. Jan 13 to Sep 302026
   Not mentioned

   Five Lilly presentations in 2026 do not mention it

   What it says. A full-text search of the slides from the JPMorgan conference (January 13), the Q1 earnings call (April 30), the ADA investor event (June 6), the Q2 earnings call (August 5) and the EASD analyst call (September 30) finds no GGG Tri-Agonist III, no LY4086940 and no NCT06945419.

   What it leaves out. Lilly’s decks show selected programs only, so a missing label does not mean the program changed. The registry shows it moving forward in the same months.

   Source: JPMorgan talk, Q1 2026 deck, ADA 2026 event, Q2 2026 deck, EASD 2026 call

8. Aug 52026
   Registry record

   The phase 1 study is marked complete

   What it says. The registry lists the study as completed on August 5, 2026, the same day as its primary completion date, with 219 participants enrolled. Lilly’s earlier slides had listed 165 and then 201 patients, and both slides had projected April 2026 for completion. The main measure was serious side effects related to the study drug through week 9.

   What it leaves out. No results are posted: no weight change, no side-effect data, no drug levels and no dose amounts.

   Source: NCT06945419

9. Oct 222026
   Registry record

   A phase 2 study is registered

   What it says. NCT07890376 was submitted October 16 and first posted October 22, 2026. It plans 460 adults aged 18 to 75 to take oral LY4086940 or a placebo. There are nine LY4086940 arms, labelled Dose 1 to Dose 6, with two titration schedules on Dose 3 and three on Dose 6. The main measure is percent change in body weight at week 32. The status is not yet recruiting, with a start listed for November 2026, primary completion in January 2028 and completion in June 2028. It lists 46 sites, 39 in the US and 7 in Argentina, and runs under a Lilly master protocol (W8M-MC-CWMM) that covers several drugs.

   What it leaves out. The dose labels carry no milligram amounts, and no results exist yet.

   Source: NCT07890376

10. Oct 302026
    Third-party report

    A tracker lists nine China tablet applications

    What it says. YaoGeJu, a Chinese drug-review tracker built on the public acceptance lists of China’s drug regulator (the CDE), shows nine entries for LY4086940 tablets accepted on October 30, 2026. Each is labelled an import application, Class 1, with Eli Lilly and Company and Lilly (Beijing) Medical Technology Innovation Co. Ltd. as applicants. The tracker’s weekly report for October 27 to November 2, 2026 ranks Lilly first by new acceptances that week, with 9 filings for 1 drug.

    What it leaves out. We have not seen the regulator’s own record, and the tracker’s drug-detail pages need a login. Nine application numbers do not mean nine strengths, and acceptance of a filing is not approval. No doses, structure or trial documents came with it, and we found no comment from Lilly.

    Source: YaoGeJu national drug-review weekly, October 27 to November 2, 2026

Still ahead

Dated events that could add a new entry. Lilly sets the dates and decides what to share.

1. Oct 292026
   Scheduled

   Lilly’s Q3 2026 earnings call, 10:00 AM ET

   What to watch. Lilly’s next earnings presentation. Its pipeline chart will show whether GGG Tri-Agonist III is listed again, whether a phase 2 entry appears, or whether the program has a new name.

   Source: Lilly event page

2. Nov2026
   Scheduled

   Phase 2 start listed in the registry

   What to watch. The record lists November 2026 as the start. When recruiting begins the status changes from not yet recruiting to recruiting, and the start date or site list may change.

   Source: NCT07890376

3. Dec 72026
   Scheduled

   Lilly Innovation Day, 9:00 AM to 1:00 PM ET

   What to watch. An investor event Lilly has scheduled. What it covers is Lilly’s to announce.

   Source: Lilly event page

What is still not public

None of the records above, and none of the other sources we have checked, gives any of the following.

• The molecular structure or amino-acid sequence. The patent application above is general and never names the code.
• Any dose amount. Both registry records use study-part and dose-level labels, not milligram amounts.
• Any result, including weight change, side effects or blood levels. The phase 1 record has no results posted.
• A nonproprietary (generic) name.
• A Lilly statement, about LY4086940 itself, of which receptors it acts on. The ADA 2025 slides label an oral GGG peptide a GLP-1, GIP and glucagon agonist, but do not name LY4086940 next to it.

For the reasoning behind the oral triple-agonist reading, see the write-up on the identity puzzle. For the trials, dose disclosure and status in one place, see the LY4086940 profile.

Questions readers ask

Cite this page

Related on PeptideBlog

• LY4086940 profile: trials, dose disclosure and status
• The identity puzzle: structure, sequence and patents
• LY4086940 vs retatrutide and LY4086940 vs orforglipron
• Clinical trial tracker: both LY4086940 studies are listed
• Retatrutide, orforglipron and eloralintide: other Lilly obesity programs
• Retzoundi and Retkouro, what Lilly’s trademark filings show, and why none is tied to a named medicine in the public record.

Elsewhere

• The Weight Loss Atlas: LY4086940, Lilly’s LY numbers explained, and its weight-loss medicine pipeline and trial tracker
• Retatrutide on The Weight Loss Atlas, the GIP, GLP-1 and glucagon program that LY4086940 is most often compared with
• EloralintideResearch: the LY4086940 landscape

Sources

1. WO2024163535A1, GIP/GLP1/GCG tri-receptor agonists and uses thereof Eli Lilly and Company. Patent application.
2. US 2024/0270821 A1, same title Eli Lilly and Company. Patent application.
3. NCT06945419, A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes ClinicalTrials.gov. Registry record.
4. NCT07890376, phase 2 study of LY4086940 ClinicalTrials.gov. Registry record.
5. Lilly investor event slides, American Diabetes Association 2025 (June 22, 2025) Eli Lilly and Company. Lilly document.
6. Lilly Q2 2025 earnings deck (August 7, 2025) Eli Lilly and Company. Lilly document.
7. Lilly Q3 2025 earnings deck (October 30, 2025) Eli Lilly and Company. Lilly document.
8. Lilly Q4 2025 earnings deck (February 4, 2026) Eli Lilly and Company. Lilly document.
9. Lilly JPMorgan conference presentation (January 13, 2026) Eli Lilly and Company. Lilly document.
10. Lilly Q1 2026 earnings deck (April 30, 2026) Eli Lilly and Company. Lilly document.
11. Lilly investor event slides, American Diabetes Association 2026 (June 6, 2026) Eli Lilly and Company. Lilly document.
12. Lilly Q2 2026 earnings deck (August 5, 2026) Eli Lilly and Company. Lilly document.
13. Lilly EASD 2026 analyst call presentation (September 30, 2026) Eli Lilly and Company. Lilly document.
14. Lilly investor events calendar Eli Lilly and Company. Lilly document.

Educational compilation of public records. It is not medical advice and does not describe any amount, schedule or regimen for any person. Presenting a record here does not endorse a drug, a claim or a study.